Global super generics market is expected to grow at significant rate owing to lack of innovation from pharmaceutical companies, increased cost of new drug development and added advantage of extended market exclusivity for improved version of super generic product. The factors currently contributing to the revenue growth of the super generics market is requirement of less time and cost of development, improved therapeutic effect, patient compliance and improved access or affordability of the treatment due to economic viability. Furthermore, increased market opportunities for generics, expected patent expiries over forecast period and increasing awareness about generics among key stakeholders are expected to drive the market for super generics over the forecast period.
Global super generics market may hindered by availability of low cost generics from developing markets and price pressure from payers which are expected to affect the market negatively over the forecast period. The super generics market is restrained by pay for delays by innovator companies, commoditization of generic market, and misuse of Risk Evaluation and Mitigation Strategies (REMS) programs by innovator companies to withhold access to drug samples for generic manufacturers’ bioequivalence testing and development, which are expected to hinder market revenue growth of super generics over the forecast period
The generics market is very competitive with several companies looking to develop newer versions of generics by adding value to the product which helps in getting the market exclusivity extension for particular brand. Large cost of drug development and time overrun for developing new therapeutic entities, hindering innovation in pharmaceutical research and developing space there by promoting the companies to look for alternatives to sustain the patent protection of the given brand.
Super generics or improved therapeutic entities are the superior form of the given generic molecule which has better patient compliance and therapeutic effect than already existing generic versions. Manufacturers adopt the quality by design, uses multifunctional excipients, modifies the dosage form and release pattern to develop value added generics i.e. super generics which create new segment of growth and assure better quality and economic viability to the payors.
Some of the players in the global super generics market are Sun Pharmaceutical Industries Ltd., Meda Pharmaceuticals Inc., Taiwan Liposome Company, Dr. Reddy’s Laboratories Ltd., Allergan plc., Teva Pharmaceutical Industries Ltd., and Celgene Corporation to name a few.
Request For Report sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4126